Health Information & Coding · Independent exam preparation
ODS Certification: Cancer Registry Decisions and Practice Guide Study Guide
Practise reportability, casefinding audits, staging distinctions, treatment coding, and ethical disclosure decisions for NCRA's entry-level ODS examination.
By CertMedbry · Updated 29 October 2026
Learn to distinguish primary cancers from metastases, investigate missing cases, interpret registry statistics, and abstract stage and treatment from documented evidence. This selective guide develops 60 decisions across all four domains of NCRA's entry-level Oncology Data Specialist examination. The official content outline defines the full scope, including topics beyond these lessons. Examples distinguish examination-listed reference editions from subsequent practice updates.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification and examination does this guide cover?
It covers the Oncology Data Specialist (ODS) Certification Examination administered by NCRA's Council on Certification. ODS is the new name of the Certified Tumor Registrar (CTR) credential; CTR is not a separate current examination. ODS, ODS-C, and ODS-Certified are synonymous credential forms.
NCRA: Are You a Credential Holder? · 2026 Exam Handbook & Candidate Application
How many questions are there, and are pretest questions identified?
The 2026 handbook specifies 180 four-option multiple-choice questions: 120 closed-book questions and 60 open-book questions. It states that all questions are included in the final score calculation, including unanswered questions and questions marked for review. It does not identify a separate unscored pretest allocation.
How much time is available?
Testing time is four hours: two hours for the closed-book section and two hours for the open-book section. A separate mandatory 15-minute break follows submission of the closed-book section. Unused time does not transfer, and candidates cannot return to the submitted first section.
How is the examination delivered, and is it adaptive?
Candidates may use a Meazure Learning computer-based testing center or online remote testing with a live proctor. The handbook describes assembled examination versions, fixed section counts, and review within the current section; it does not describe computer-adaptive delivery. Questions assess recall, application, and analysis, with emphasis on application and analysis.
Which blueprint applies, and how are the domains weighted?
NCRA currently links the outline updated December 2, 2022, introduced beginning in 2023 and based on the 2022 role delineation study. The counts are Legal and Ethical Aspects in the Cancer Registry Profession, 30; Cancer Registry Operations, 45; Cancer Registry Data Identification, 45; and Cancer Registry Coding and Abstraction, 60. Calculated shares are approximately 16.67%, 25%, 25%, and 33.33%. This selective guide uses 10/15/16/19 concepts and 3/5/5/7 questions and flashcards, respectively. The official outline defines the full examination scope.
Which reference editions should govern 2026 examination preparation?
The examination reference list updated December 16, 2025, specifies editions including STORE 2025 updated April 2025, Solid Tumor Rules dated December 2024, Summary Stage 2018 v3.3 dated November 2025, Grade Manual v3.2, selected AJCC eighth-edition sites, and Lung Version 9. Later Solid Tumor Rules and Summary Stage v3.4 are supplementary practice references; their revisions do not automatically replace the examination-listed editions.
References for ODS Certification Examinations in 2026 · SEER: Solid Tumor Rules · SEER: Summary Stage 2018
How does the open-book section work?
Cancer Registry Coding and Abstraction is the 60-question open-book section. The examination platform supplies the permitted references as searchable PDFs. Candidates must not bring their own references. The handbook states that the open-book section may test any primary site.
Do the eligibility routes lead to different examinations?
The handbook describes three eligibility routes to the same ODS examination. Routes 1 and 2 involve an NCRA-accredited educational program and its practicum, with their respective degree requirements. Route 3 combines specified college education, anatomy and physiology coursework, and cancer registry experience. This guide addresses the shared examination, rather than a separate route-specific test.
What passing score and practice-test interpretation are supported?
The handbook describes a combined examination score and a passing point established using the Modified-Angoff method; it does not provide a numerical passing score in the supplied examination description. These 20 original questions are independent learning drills. Their results identify topics for further study and do not predict certification outcomes.
ODS is the renamed Certified Tumor Registrar credential, with implementation beginning January 1, 2024. This independent educational guide addresses NCRA's cancer registry certification and is not endorsed by NCRA.
Outline used: 2026 Exam Handbook, dated December 2025; currently adopted content outline updated December 2, 2022, used beginning in 2023; 2026 examination references updated December 16, 2025. NCRA renamed Certified Tumor Registrar (CTR) to Oncology Data Specialist (ODS), with implementation beginning January 1, 2024. The assigned CTR slug is preserved for this same renamed credential and examination.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Legal and Ethical Aspects in the Cancer Registry Profession16.67% (30 of 180 items; calculated)
1.When may cancer information be disclosed for public health reporting?
Under U.S. HIPAA, a covered entity may disclose protected health information without individual authorization to a public health authority legally authorized to collect it for public health purposes. The decisive facts are the recipient's authority and the purpose of the disclosure. A cancer registry's name alone does not establish either. Verify the reporting destination, applicable authority, and requested information before treating a disclosure as authorized public health reporting.
Apply it
A state cancer registry requests a newly diagnosed resident's report under its established surveillance authority. The registrar verifies the recipient and reporting authority, then processes the authorized report without seeking a separate patient authorization for that disclosure.
Common pitfall: Do not assume that every organization studying cancer is a public health authority. A research interest or familiar institutional name does not establish disclosure authority.
HHS: Patient Permission and Reporting to Public Health Authorities
2.Why does HIPAA permission differ from a reporting obligation?
HIPAA's public health provision permits qualifying disclosures; it does not itself require every permitted disclosure. A separate law may impose a reporting obligation, including which cancers, facilities, residents, or data elements are covered. Distinguish the legal permission to disclose from the duty to submit. This distinction prevents both unnecessary authorization barriers and the mistaken conclusion that a permissive federal provision makes mandatory state reporting optional.
Apply it
A facility argues that reporting is optional because HIPAA says it may disclose. The registrar identifies the separate state reporting requirement and explains that HIPAA permission and the state-imposed reporting duty answer different legal questions.
Common pitfall: Neither 'HIPAA allows it' nor 'HIPAA does not require it' resolves whether another applicable law mandates the report or establishes its submission deadline.
3.How should a registrar establish authority for an information release?
A release decision requires an identified recipient, a defined purpose, and a valid legal or institutional basis for providing the requested information. Possession of a record does not authorize unrestricted redistribution. Determine whether the request concerns mandated reporting, another permitted use, or a release needing additional authorization or review. The discriminating cue is the documented basis for this specific disclosure, rather than the requester's professional status or urgency.
Apply it
An oncologist at another organization asks for a named patient's registry abstract for an unspecified project. The registrar verifies identity, clarifies the purpose, and establishes the applicable release authority before supplying identifiable information to that requester.
Common pitfall: A clinician's title does not automatically authorize every requested registry use. Access for one purpose also does not establish permission for a different purpose.
NCRA Professional Practice Code of Ethics · ODS Certification Exam Content Outline
4.Which information belongs in an authorized disclosure?
A justified disclosure still needs a defined information boundary. Match the released fields to the applicable reporting requirement or approved purpose, and distinguish required identifiers from unrelated clinical material. This protects confidentiality while preserving useful, complete reporting. A full medical record and a specified registry submission are different products. The practical decision is whether each included field serves the authorized disclosure, using the governing rules rather than convenience.
Apply it
A reporting specification requires identifiers, diagnosis, stage, and treatment fields. A proposed export also contains unrelated psychotherapy notes. The registrar removes material outside the authorized submission and checks that the required cancer reporting fields remain complete.
Common pitfall: Do not equate confidentiality with deleting all identifiers from a required report. Conversely, an authorized report does not justify automatically attaching the entire medical record.
NCRA Professional Practice Code of Ethics · HHS: Patient Permission and Reporting to Public Health Authorities
5.How should access to registry records follow work responsibilities?
Confidentiality depends on limiting record access to legitimate professional functions, not merely protecting records from outsiders. Registry employment does not create a personal entitlement to inspect every patient's history. Access should correspond to assigned reporting, abstraction, quality, or other authorized duties. A useful discriminating cue is whether the employee can identify a current work purpose for viewing the record and whether that purpose is within the employee's authorized role.
Apply it
A registrar recognizes a neighbor's name in the work queue but has no assignment involving that case. Curiosity is not a registry function, so the registrar does not open the record or discuss the patient's presence.
Common pitfall: Knowing a patient personally makes confidentiality more consequential; it does not provide consent. Technical ability to open a record is separate from professional authority.
6.How can a registrar prevent disclosure to the wrong recipient?
A correct disclosure purpose can still lead to a confidentiality failure if the information reaches the wrong destination. Verify the recipient's identity, organizational role, and approved delivery details before transmitting identifiable records. Use established secure channels and investigate discrepancies instead of relying on a familiar display name. The mechanism is prevention of misdirection: legal authority for the intended recipient does not transfer to an unintended recipient or an unverified address.
Apply it
A message requests cancer abstracts using a display name matching the state registry, but the destination differs from the approved reporting channel. The registrar confirms the request through established contact information before transmitting any patient records.
Common pitfall: Encryption does not correct a mistaken recipient. A securely delivered file can still breach confidentiality when sent to an unauthorized person or destination.
7.When may identifiable registry information be disclosed for research?
For research disclosure of PHI by a HIPAA-covered entity, two principal pathways are a valid individual HIPAA authorization covering the proposed disclosure or a documented authorization waiver from an IRB or Privacy Board. A waiver requires no more than minimal privacy risk, supported by plans to protect identifiers, destroy them at the earliest appropriate opportunity unless retention is justified, and written assurances against unauthorized reuse or disclosure. The research must also be impracticable without both the waiver and access to the PHI. Research protocol approval alone does not establish authorization to disclose PHI. These criteria are described in [HHS research guidance](https://www.hhs.gov/hipaa/for-professionals/special-topics/research/index.html).
Apply it
An investigator requests named records for a retrospective linkage study. An IRB approval letter alone is insufficient. The registrar checks for individual authorizations or documented waiver findings addressing identifier safeguards, justified retention, limits on reuse, and why the study cannot practicably proceed without the waiver and identifiable records. Any additional applicable disclosure restrictions must also be satisfied.
Common pitfall: A public health reporting mandate does not automatically authorize a later research disclosure. Scientific merit, institutional affiliation, and ordinary IRB study approval do not substitute for a HIPAA authorization or a documented applicable waiver.
NCRA Professional Practice Code of Ethics · ODS Certification Exam Content Outline
8.Why must abstract corrections preserve an honest record?
Registry integrity requires data to reflect supported documentation and corrections to remain accountable. When new evidence changes an abstract, record the supported value and preserve the explanation required by the registry's correction process. An unfavorable result is not a reason to alter a valid value. The discriminating question is whether the change corrects a documented error or instead changes the appearance of performance without a defensible evidentiary basis.
Apply it
An audit finds that a positive surgical margin was abstracted as negative. The registrar corrects the field using the pathology report and records the reason, even though the correction worsens the program's reported margin outcome.
Common pitfall: Do not protect a quality indicator by retaining a known error. Equally, do not overwrite an accurate field merely because a supervisor prefers another result.
9.How should conflicts of interest affect registry decisions?
A conflict exists when personal, financial, or professional interests could influence the impartial handling or interpretation of registry information. Disclose the relevant relationship and use an appropriate independent review or reassignment process. The issue is not limited to proven misconduct; a relationship can threaten confidence before a biased decision occurs. Data definitions and documented evidence must govern the result rather than loyalty to a colleague, employer, sponsor, or desired conclusion.
Apply it
A registrar evaluating disputed cases also consults for the vendor whose software produced the errors. The registrar discloses that relationship and arranges independent review of the findings before the organization makes its quality assessment.
Common pitfall: Believing that you can remain fair does not eliminate a relevant conflict. Disclosure should occur before the relationship undermines the credibility of the work.
10.How should registry findings be communicated ethically?
Ethical reporting presents findings with their population, definitions, and material limitations intact. Removing inconvenient cases or hiding incomplete ascertainment can mislead readers even when the displayed arithmetic is correct. Distinguish observed associations from established causes and avoid implying that a selected facility series represents an entire community. The decision cue is whether another qualified reader could understand what was measured, which records were included, and what the evidence actually supports.
Apply it
A report shows fewer late-stage cases after an intervention, but one major reporting source is missing. The registrar explains the incomplete ascertainment and postpones a causal claim until the missing source's contribution can be evaluated.
Common pitfall: Accurate arithmetic does not make a selectively framed conclusion honest. A favorable trend can reflect changing coverage or case selection rather than improved cancer outcomes.
NCRA Professional Practice Code of Ethics · SEER Training: Assessing Completeness
Cancer Registry Operations25% (45 of 180 items)
11.How do facility and population-based registry purposes differ?
A facility registry describes patients diagnosed or treated within its institutional scope, supporting patient care evaluation and program activities. A population-based registry seeks reportable cancers among residents of a defined geographic population, including residents treated elsewhere. The membership rule determines interpretation. Facility counts reflect referral and service patterns as well as disease occurrence; population surveillance requires geographic ascertainment rather than simply combining the patients seen at one hospital or health system.
Apply it
A tertiary hospital reports many rare tumors from distant referrals. Its registry can describe that treated population, but estimating regional incidence requires a population-based registry that identifies resident cases across all relevant reporting sources.
Common pitfall: A large facility registry is not automatically population-based. High patient volume does not establish complete ascertainment of cancers among residents of a geographic area.
12.Why must incidence numerators match their population denominators?
An incidence measure relates newly occurring cancers to the population in which those cancers arose during a defined period. Numerator eligibility and denominator membership must therefore agree on geography, time, and relevant population characteristics. Including nonresident referral cases while using only local residents in the denominator inflates the apparent local occurrence. Conversely, missing residents treated outside the area reduces ascertainment. The decisive check is membership consistency, not the size of the dataset.
Apply it
A county hospital counted 90 resident diagnoses and 30 nonresident referrals. An analyst proposes using all 120 cases with the county population. The registrar restricts the numerator to eligible residents and seeks resident cases diagnosed elsewhere.
Common pitfall: The hospital's service area and the county's resident population may differ. A convenient denominator does not make an unmatched numerator a valid incidence measure.
13.Which questions can a specialty registry answer reliably?
A specialty registry restricts its focus, such as to a particular cancer, treatment, or clinical population. That focus can provide detailed information unavailable in a broad registry, but its inclusion criteria define the conclusions it can support. Evaluate whether the registry captures all eligible people or only participants at selected centers. Detailed disease information does not remove selection effects, and a specialty cohort does not automatically support general population incidence estimates.
Apply it
A registry follows patients receiving a specialized cellular therapy at participating centers. It can describe outcomes within that enrolled treatment cohort, but the registrar avoids presenting its enrollment count as the total number of cancers in the region.
Common pitfall: Rich clinical detail does not guarantee representative coverage. A registry organized around treatment participation may omit eligible patients who never received that treatment.
ODS Certification Exam Content Outline · SEER Training: Population-Based Registries
14.Which organizations supply pathology, accreditation, data, surveillance, and treatment standards?
[CAP](https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates), the College of American Pathologists, supplies cancer pathology reporting protocols. [CoC](https://www.facs.org/quality-programs/cancer-programs/commission-on-cancer/), the Commission on Cancer, establishes cancer program accreditation requirements and registry collection requirements expressed in STORE. [NAACCR](https://www.naaccr.org/data-standards-data-dictionary/) standardizes registry data definitions, codes, and exchange specifications. [NCCN](https://www.nccn.org/guidelines/category_1), the National Comprehensive Cancer Network, develops clinical management guidelines. CDC's [NPCR](https://www.cdc.gov/cancer/npcr/) supports state and territorial population-based surveillance and establishes requirements for participating programs. NCI's [SEER](https://seer.cancer.gov/) conducts population-based surveillance and publishes registry coding and collection guidance. Their functions overlap, but their requirements serve different purposes.
Apply it
For a colectomy pathology checklist, select the CAP colon protocol. For a cancer program accreditation obligation, select the applicable CoC standard. For the definition and exchange format of a registry field, use NAACCR specifications. For treatment recommendations, use the relevant NCCN guideline. For a surveillance submission, apply the receiving registry's NPCR or SEER requirements and any additional jurisdictional requirements.
Common pitfall: A CAP pathology protocol does not define every registry submission field. A treatment guideline does not establish what treatment was administered. A NAACCR-defined item is not automatically required by every receiving program.
ODS Certification Exam Content Outline · Standards for Oncology Registry Entry: STORE 2025
15.What does a single-field edit establish?
A single-field edit checks whether a value satisfies that field's permitted format, range, or code set. It can identify an impossible date format or a code outside the allowed list, but a permitted value can still be wrong for the patient. Passing the edit therefore establishes conformity to a defined rule, not agreement with the source record. Use edits to locate potential problems and source review to establish the supported clinical value.
Apply it
An abstract contains a valid laterality code, so the field passes its code-list edit. Reabstraction shows the opposite side in the operative and pathology reports. The registrar corrects the clinically inaccurate value despite the successful edit.
Common pitfall: Edit acceptance is not proof of accuracy. A valid code can describe the wrong side, site, date, or treatment while remaining technically acceptable.
ODS Certification Exam Content Outline · SEER Training: Assessing Completeness
16.How should a central registry resolve an edit created during consolidation?
A central registry receives reports from multiple sources and must reconcile records belonging to the same patient and primary. Individually valid source values can become inconsistent when combined into a consolidated tumor record. Establish that the reports concern the same primary, identify the contributing sources and assessment dates, and compare the original evidence. Correct the unsupported value, preserve the basis for consolidation, provide source feedback when warranted, and rerun the applicable edits. An edit identifies the disputed relationship; it does not establish which source is correct.
Apply it
Two hospitals report the same untreated sigmoid primary. The surgical hospital reports pN1a and one positive regional node; the oncology hospital reports zero positive nodes. Consolidation selects pN1a from the surgical report and zero positive nodes from the oncology report, triggering a consistency edit. The original resection pathology confirms one of 18 regional nodes positive. The central registrar corrects the consolidated node count, documents its source, requests correction of the erroneous hospital submission, and reruns the edit.
Common pitfall: Do not create two incident primaries merely because two facilities reported the patient. Do not resolve the discrepancy by automatically choosing the largest value, the newest submission, or the field easiest to change; those shortcuts can combine different assessments or preserve an error.
ODS Certification Exam Content Outline · Colon Cancer Treatment (PDQ®) - NCI · NCRA Professional Practice Code of Ethics
17.Why are completeness and accuracy separate quality dimensions?
Completeness asks whether all eligible cases or required information have been captured; accuracy asks whether captured information correctly represents the source evidence. A registry can accurately abstract every recorded case while missing many eligible patients. It can also identify nearly every patient but miscode important fields. Evaluate both dimensions independently because each produces different biases and requires different corrective work. Successful reabstraction of existing records cannot establish that missing cases do not exist.
Apply it
Reviewers find 99% agreement in sampled histology fields, but an independent outpatient list reveals unregistered cancers. The manager retains the accuracy finding and separately investigates casefinding completeness rather than treating one result as evidence for both.
Common pitfall: A clean existing database can still be incomplete. Quality review confined to registered records cannot directly identify patients who never entered the registry.
SEER Training: Assessing Completeness · SEER Training: Casefinding Audits and Process Improvement
18.How does an independent casefinding audit expose missed patients?
A casefinding audit compares the registry against another source capable of identifying potentially eligible cases. Independence matters because reviewing only the registry's own case list repeats the original omissions. Match records, investigate unmatched entries, determine reportability, and distinguish true misses from duplicates or exclusions. The decisive evidence is a confirmed reportable case absent from the registry, rather than every unmatched name. Audit findings should identify the source or workflow responsible for the gap.
Apply it
An auditor compares an independently compiled radiation treatment list with registry accessions. Several unmatched entries are benign conditions, but four are reportable cancers. Those confirmed omissions trigger case accession and investigation of the radiation source review process.
Common pitfall: Unmatched does not automatically mean missed and reportable. Conversely, reviewing a sample drawn only from registered patients cannot establish independent casefinding completeness.
19.How should an audit's missed-case percentage be calculated?
Define the denominator before calculating a missed-case percentage. If an audit independently establishes the total eligible cases in its reviewed population, divide confirmed missed eligible cases by that total and multiply by 100. Do not substitute all screened records, all unmatched entries, or only previously registered cases. The resulting percentage describes the audited population; extending it to the whole registry requires attention to how the audit cases were selected and which sources they represent.
Apply it
An independent audit confirms 200 eligible cases: 176 already registered and 24 missed. The missed-case percentage is 24 divided by 200, or 12%. The registrar reports the audited source and period alongside the result.
Common pitfall: Dividing missed cases by registered cases answers a different question. Also exclude confirmed nonreportable records from an eligible-case denominator rather than diluting the missed-case percentage.
SEER Training: Casefinding Audits and Process Improvement · SEER Training: Assessing Completeness
20.How does quality improvement turn audit findings into prevention?
Quality control detects problems in current records or processes; quality improvement changes the process that produces those problems and evaluates whether the change works. Link a recurring omission to its cause, implement a targeted intervention, and repeat a comparable measurement. Counting corrected cases alone demonstrates cleanup, not prevention. A useful discriminating cue is whether the follow-up assessment tests the same failure mechanism under sufficiently comparable conditions after the process change was introduced.
Apply it
An audit traces missed outpatient cancers to an excluded clinic feed. The registry adds that feed, assigns review responsibility, and repeats an independent clinic comparison for a later period to assess whether the omission problem has decreased.
Common pitfall: Training everyone without identifying the failed step may leave the cause untouched. Correcting old records also does not establish that future omissions have been prevented.
SEER Training: Casefinding Audits and Process Improvement · ODS Certification Exam Content Outline
21.Why do several casefinding sources improve ascertainment?
Different clinical pathways leave evidence in different systems. Pathology can identify tissue diagnoses, while treatment, imaging, discharge, or clinic sources can identify patients absent from a pathology-only workflow. Compare source coverage and reconcile overlaps so adding a source increases ascertainment without creating duplicate tumors. The important operational question is which eligible patients a source can uniquely reveal. More records are useful only when their contribution is evaluated against the registry's reporting scope.
Apply it
A registry's pathology feed is complete, but a review of oncology visits identifies clinically diagnosed cancers without local tissue specimens. The manager adds a targeted clinic source and reconciles its cases with existing accessions before assessing completeness.
Common pitfall: Complete capture of one source does not mean complete capture of cancer cases. Counting overlapping source entries as separate patients can falsely suggest improved ascertainment.
SEER Training: Casefinding Introduction · SEER Training: Assessing Completeness
22.When is the median preferable for a skewed registry measure?
The median is the middle ordered observation, or the average of the two middle observations when the number is even. It is resistant to extreme values because its position depends on order rather than the magnitude of every observation. For strongly right-skewed processing times, the median often describes a typical case more clearly than the mean. It does not eliminate the need to investigate unusually long delays or describe the distribution's spread.
Apply it
Processing times are 4, 6, 7, 8, and 75 minutes. The median is 7 minutes, while the mean is 20 minutes. The manager uses the median for typical processing and separately examines the unusually delayed case.
Common pitfall: Resistance to outliers does not make the median a complete performance summary. A stable median can coexist with a clinically or operationally important delayed subgroup.
23.How do the mean and mode answer different descriptive questions?
The arithmetic mean divides the sum of numerical observations by their count and therefore reflects every observation's magnitude. The mode identifies the most frequent value or category and can describe categorical data for which arithmetic averaging is meaningless. Select the measure according to the question and measurement scale. An average processing time and the most common primary site summarize different features; neither should be substituted for the other merely because both are measures of location.
Apply it
A manager wants the most common primary-site category and average abstraction minutes. The registrar reports the modal site category and calculates mean minutes from numerical times, rather than averaging the numerical labels assigned to site categories.
Common pitfall: Numeric category codes are labels, not quantities. Their arithmetic mean usually has no clinical meaning, even though software can calculate it without an error.
24.How is a risk ratio calculated from cohort data?
A risk ratio divides the outcome risk in one group by the outcome risk in the comparison group. Each risk uses people with the outcome over all people at risk in that group during the specified period. This calculation requires meaningful group denominators, rather than case counts alone. A ratio above one indicates a higher observed risk in the numerator group, but does not establish causation or correct differences in follow-up and other confounders.
Apply it
Over the same follow-up period, 18 of 300 exposed people and 12 of 600 unexposed people develop the outcome. Their risks are 0.06 and 0.02, giving a risk ratio of 3 for exposed versus unexposed.
Common pitfall: The ratio of outcome counts, 18 divided by 12, ignores unequal group sizes. State which group is in the numerator before interpreting the ratio.
CDC Field Epidemiology Manual: Analyzing and Interpreting Data
25.Why is an odds ratio useful in a case-control study?
Case-control sampling selects people by outcome status, so sampled case and control totals do not directly provide population risks. The odds ratio compares exposure odds among cases with exposure odds among controls. With cells defined as exposed cases a, exposed controls b, unexposed cases c, and unexposed controls d, the odds ratio is ad divided by bc. Interpret it as an odds association; it is not automatically numerically equivalent to a risk ratio.
Apply it
A case-control study has 30 exposed cases, 20 exposed controls, 10 unexposed cases, and 40 unexposed controls. The odds ratio is (30 × 40)/(20 × 10) = 6, comparing exposure odds among cases with controls.
Common pitfall: Do not calculate disease risk from deliberately sampled case and control totals. An odds ratio should not be called a sixfold risk without additional justification.
CDC Field Epidemiology Manual: Analyzing and Interpreting Data
Cancer Registry Data Identification25% (45 of 180 items)
26.How do anatomy and specimen terminology guide primary-site identification?
Primary-site identification concerns where a cancer originated, which may differ from the organ or compartment sampled. Read the specimen label together with the final diagnosis, clinical history, and anatomic description. Terms identifying tissue layers, adjacent structures, or metastatic involvement can change the interpretation of a familiar organ name. The key decision is whether the record describes origin in that structure or involvement by a cancer originating elsewhere; specimen location alone cannot resolve that distinction.
Apply it
A liver core specimen contains carcinoma that the final diagnosis identifies as metastatic colorectal adenocarcinoma. The registrar records the liver as the sampled metastatic site and evaluates the colorectal origin rather than treating the specimen label as primary-site proof.
Common pitfall: An organ named on a specimen container identifies where tissue was obtained. It does not necessarily identify the primary cancer or a new reportable primary.
NCI: Metastatic Cancer—When Cancer Spreads · NCI: Pathology Reports
27.Why does metastatic cancer retain the identity of its primary?
Metastasis occurs when cancer cells spread from the primary site and form tumors elsewhere. The metastatic cells retain characteristics of the originating cancer, so breast cancer in the lung remains metastatic breast cancer rather than becoming primary lung cancer. A new organ lesion can alternatively represent a separate primary, but that conclusion requires supporting diagnostic evidence. The discriminating cue is the documented relationship between the lesion and the known cancer, not merely the organ involved.
Apply it
A patient with prior breast cancer has a lung biopsy explicitly diagnosed as metastatic breast carcinoma. The registrar links the deposit to the breast malignancy rather than creating a lung primary solely because the new lesion is pulmonary.
Common pitfall: Do not assume every lesion in a cancer survivor is metastatic either. A documented independent primary requires different handling from a confirmed metastatic deposit.
28.How do histologic type and tumor grade differ?
Histologic type identifies the kind of tumor based on its cellular and tissue characteristics; grade describes features such as differentiation or other tumor-specific measures of aggressiveness. These answer different questions and should be abstracted from their respective documented findings. A named carcinoma type does not establish its grade, and a high-grade description does not identify a unique histology. Recognize the distinction before applying the relevant histology and grade coding instructions.
Apply it
A pathology report describes adenocarcinoma and separately calls it poorly differentiated. The registrar treats adenocarcinoma as the tumor type and the differentiation statement as grade information, then applies the appropriate coding instructions to each field.
Common pitfall: Avoid converting an aggressive-sounding histologic name into an assumed grade. Likewise, 'high grade' alone does not supply a specific tumor type or primary site.
NCI: Pathology Reports · References for ODS Certification Examinations in 2026
29.How do site, behavior, diagnosis date, and receiving program determine reportability?
Reportability requires applying a specific program's eligibility instructions to the documented site, histology, behavior, and diagnosis date. STORE 2025 requires qualifying nonmalignant intracranial and central nervous system tumors diagnosed on or after January 1, 2004. Thus benign behavior does not exclude a tumor at a qualifying site. STORE also distinguishes program requirements: LCIS alone is not required by CoC, but is required by SEER and NPCR. A facility's CoC collection obligation therefore does not establish the complete scope of its central-registry reporting obligation.
Apply it
Consider three 2025 diagnoses within the otherwise applicable reporting scope. A benign intracranial meningioma qualifies for CoC collection because its meningeal site meets the nonmalignant CNS inclusion criterion and its diagnosis follows January 1, 2004. A benign breast fibroadenoma does not qualify through that exception because its site is outside the specified intracranial/CNS group. Breast LCIS alone has in situ behavior, but CoC does not require its collection; SEER and NPCR do. Apply the receiving central registry's requirements when preparing that submission.
Common pitfall: Do not exclude every benign tumor, include every in situ lesion for every program, or apply the 2004 nonmalignant CNS start date to all tumors. Keep the diagnosis date, qualifying site, behavior, and recipient's requirements together in the decision.
Standards for Oncology Registry Entry: STORE 2025 · SEER Training: Casefinding Introduction
30.How does casefinding differ from completed abstraction?
Casefinding identifies and tracks people or tumors that may meet reporting criteria; abstraction converts the relevant clinical record into required registry data. A candidate can remain under investigation while diagnosis, eligibility, or missing records are resolved. Maintaining that distinction prevents preliminary signals from becoming unsupported finalized data and prevents unresolved candidates from disappearing. The key workflow cue is whether the case has merely been identified for review or has enough evidence for a completed reporting decision.
Apply it
An imaging list identifies a possible pancreatic malignancy without a final diagnosis in the local chart. The registrar adds a tracked casefinding candidate, requests the outside diagnostic record, and postpones final abstraction until the missing evidence is evaluated.
Common pitfall: A casefinding entry is not proof of malignancy. Conversely, absence of a complete local chart is a reason to investigate, not silently discard the candidate.
31.Why must pathology review account for missing and amended reports?
Pathology casefinding requires a controlled review process that can identify unreviewed, missing, and subsequently amended reports. A final diagnosis or addendum may change a preliminary interpretation, identify a malignancy, or refine an already known tumor. Track report receipt and review status rather than assuming that a daily batch contains every relevant document. The discriminating issue is whether the registry has evaluated the complete applicable pathology evidence, including later information tied to the same specimen.
Apply it
A specimen log shows an accession without a report in the registry feed. The registrar requests the missing report and later reviews its diagnostic addendum, ensuring the casefinding decision reflects the completed pathology interpretation rather than an incomplete batch.
Common pitfall: A missing report cannot be treated as a negative finding. A previously reviewed specimen also needs attention when a later amendment changes the diagnostic interpretation.
32.Which pathology sections answer different abstraction questions?
A pathology report combines specimen identification, clinical information, gross examination, microscopic findings, final diagnosis, and sometimes additional studies or structured summaries. These sections are complementary rather than interchangeable. The final diagnosis states the pathologist's integrated interpretation, while measurements, margins, and other findings may appear elsewhere. Read the relevant sections together and incorporate amendments. A clinical history copied into the report is not automatically the pathologist's confirmed diagnosis of the submitted specimen.
Apply it
The clinical history says 'possible sarcoma,' but the final diagnosis identifies a benign lesion. The registrar uses the final interpretation for the pathology conclusion and does not promote the historical suspicion into a confirmed malignant histology.
Common pitfall: Do not abstract from the first familiar phrase in a report. Clinical history, gross description, and final diagnosis serve different purposes and can contain different levels of certainty.
33.What does a surgical margin finding establish?
A margin is the edge of tissue removed during surgery. A positive margin means cancer is present at that examined edge; a negative margin means it is not identified there. This describes the resected specimen's boundary, not the absence of cancer throughout the patient. Interpret margin findings in relation to the procedure and report. Do not use a negative margin as a substitute for information about lymph nodes, distant spread, or overall stage.
Apply it
A resection has negative margins, while a separately sampled regional lymph node contains metastasis. The registrar retains both findings because clear specimen edges and nodal involvement describe different aspects of disease and are not contradictory results.
Common pitfall: Negative margins do not mean node-negative disease, no metastases, or guaranteed cure. Positive margins also do not independently establish a distant metastatic category.
34.How do PET, MRI, endoscopy, and biopsy contribute different diagnostic evidence?
PET depicts radiotracer distribution; FDG-PET reflects glucose-related metabolic activity, which can occur in malignancy and in nonmalignant processes such as inflammation. MRI uses magnetic fields and radiofrequency signals to produce detailed anatomic images, including relationships between a mass and surrounding soft tissues. Endoscopy directly inspects an accessible internal surface and can guide biopsy. Biopsy supplies cells or tissue for pathological interpretation. Imaging and visual examination can define suspected location and extent without independently establishing a microscopic histologic type; a limited biopsy may establish histology without sampling the deepest invasion.
Apply it
Colonoscopy identifies a sigmoid mass and obtains a superficial biopsy showing adenocarcinoma. That biopsy supports the histologic diagnosis, but its failure to show deep invasion does not establish that the tumor is confined to the mucosa. MRI describes the mass's relationship to surrounding structures. An FDG-avid distant focus raises a staging question, but uptake alone does not prove metastatic adenocarcinoma. Record each procedure's finding and the completed interpretation rather than treating all positive tests as equivalent evidence.
Common pitfall: Do not equate FDG uptake with cancer, an MRI appearance with a specific histology, or a negative superficial sample with absence of deeper tumor. An endoscopic impression and the resulting pathology report answer different questions.
ODS Certification Exam Content Outline · NCI: Pathology Reports · Colon Cancer Treatment (PDQ®) - NCI
35.How are hematopoietic primary count, primary site, and histology determined?
The Hematopoietic Database identifies entities, synonyms, histology codes, diagnostic information, and relationships among diagnoses. The multiple-primary rules determine how many primaries to abstract. The primary-site and histology rules determine the site and histology for each resulting primary; specimen location alone does not settle either decision. The same hematopoietic histology at several locations can represent one primary. A provisional diagnosis refined during the same workup also need not represent an additional malignancy.
Apply it
A cervical-node biopsy establishes diffuse large B-cell lymphoma, and marrow evaluation identifies involvement by that same lymphoma with no second entity. Abstract one primary despite two involved locations. In SEER's separate worked example, provisional myeloproliferative neoplasm 9975/3 is refined by the completed workup to essential thrombocythemia 9962/3. The Database links the entities as the same primary; the final result is one primary with histology 9962/3. Apply the PH rules separately to select primary site.
Common pitfall: Do not create one primary per involved organ or provisional diagnosis. A positive JAK2 result alone does not establish essential thrombocythemia; the example requires the integrated definitive diagnosis.
The Multiple Primary Rules (M rules)/Primary site and Histology Rules (PH rules) | SEER Training · ODS Certification Exam Content Outline
36.How do RT-PCR and FISH detect different kinds of laboratory evidence?
In reverse-transcription PCR, RNA is converted to complementary DNA and a selected sequence is amplified, allowing detection of a target transcript such as a fusion transcript. FISH uses fluorescent nucleic-acid probes that bind selected DNA regions in cells; signal patterns can reveal a specified rearrangement or gene amplification. Thus RT-PCR tests selected RNA-derived sequences, while FISH examines selected DNA targets in their cellular context. NCI defines [RT-PCR](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/reverse-transcription-polymerase-chain-reaction) and [FISH](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/fluorescence-in-situ-hybridization).
Apply it
An RT-PCR report detects a BCR::ABL1 transcript; a separate FISH report identifies a BCR::ABL1 rearrangement. Record the test method, target, specimen, and reported interpretation separately. These results describe the same molecular relationship through different measurements, rather than automatically establishing two diseases. Integrate them with the definitive hematologic diagnosis.
Common pitfall: A negative targeted assay does not exclude every genetic abnormality. Distinguish a negative result from test failure or insufficient material. Reverse transcription and real-time measurement describe different laboratory features, even when one assay uses both.
NCI: Biomarker Testing for Cancer Treatment · The Multiple Primary Rules (M rules)/Primary site and Histology Rules (PH rules) | SEER Training
37.How does tumor biomarker testing differ from inherited genetic testing?
Tumor biomarker testing examines features of a person's cancer that may inform diagnosis or treatment selection. Inherited genetic testing examines variants that may be present throughout the body and passed within families. A finding in tumor tissue does not automatically establish that it is inherited. Some tumor findings may prompt separate evaluation for hereditary risk. The decisive distinction is the test's purpose, specimen context, and interpretation, rather than the fact that both tests can examine genes.
Apply it
A tumor sequencing report identifies a potentially actionable variant. The registrar records the documented tumor result without labeling the patient as having an inherited syndrome, while recognizing that clinicians may recommend separate germline evaluation based on the finding.
Common pitfall: Do not equate a tumor mutation with a hereditary diagnosis. Also avoid assuming that a negative tumor panel excludes every inherited cancer susceptibility.
38.How do prognostic and predictive information differ?
Prognostic information concerns the likely course or outcome of disease, while predictive information concerns the likelihood of response to a particular treatment. A biomarker can serve one or both roles in a defined clinical context. Record the actual result and its documented interpretation rather than inferring treatment benefit from a generally unfavorable prognosis. A predictive finding also does not prove that a treatment was prescribed, administered, effective, or appropriate for every patient with that result.
Apply it
A report identifies a biomarker associated with eligibility for a targeted therapy, but the treatment record contains no administration. The registrar captures the biomarker finding and separately verifies treatment, avoiding an inferred treatment code from molecular eligibility alone.
Common pitfall: An actionable finding is not an administration record or a guarantee of response. Keep the test result, treatment decision, and observed outcome as separate facts.
NCI: Biomarker Testing for Cancer Treatment · ODS Certification Exam Content Outline
39.How do diagnosis and mechanism distinguish cancer treatment modalities?
Surgery removes tissue; radiation damages cells within a treated field; cytotoxic chemotherapy disrupts processes such as DNA replication or cell division. Endocrine therapy blocks hormone production or signaling, while targeted therapy acts on a selected molecular target. For example, tamoxifen has an endocrine role in hormone-receptor-positive breast cancer, whereas trastuzumab targets HER2 in appropriately selected HER2-positive disease. These mechanisms explain why the tumor's diagnosis and biomarkers matter. See NCI's descriptions of [treatment types](https://www.cancer.gov/about-cancer/treatment/types).
Apply it
A patient with ER-positive, HER2-positive invasive breast cancer has documented breast surgery, external-beam radiation, cytotoxic chemotherapy, tamoxifen, and trastuzumab. Identify surgery, radiation, chemotherapy, endocrine therapy, and HER2-directed treatment separately. For registry fields, use the applicable agent classification rather than assuming that every infused drug is chemotherapy. Verify actual delivery and dates from treatment records.
Common pitfall: Biomarker eligibility does not prove that treatment was received. Route of administration does not determine treatment category, and surgery or radiation does not substitute for documentation of systemic therapy.
NCI: Biomarker Testing for Cancer Treatment · Standards for Oncology Registry Entry: STORE 2025
40.How does follow-up separate patient identity, vital status, and cancer status?
Follow-up information must belong to the correct patient and describe the particular status actually established. A recent contact can confirm that a patient was alive on a date without establishing freedom from recurrence. A cancer assessment may add disease information but still needs reliable identity matching and dating. Verify the contact source and supported facts before updating fields. The discriminating cue is what the follow-up evidence demonstrates, rather than how recently any record happened to appear.
Apply it
A reliable identity-matched clinic contact documents that the patient attended an unrelated visit last month. The registrar can use the supported living contact information but does not infer no recurrence without an appropriate cancer-status assessment.
Common pitfall: Recent contact is not synonymous with disease-free status. A same-name record also cannot support follow-up until identity is sufficiently verified through the applicable matching process.
44.How are required data items selected for a specific registry submission?
Select required items by receiving program, diagnosis year, case eligibility, and any site-specific conditions. CoC's STORE includes facility-oriented items such as Class of Case and Date of First Contact. Class of Case describes the facility's diagnostic and treatment relationship to the case; Date of First Contact identifies its first qualifying cancer-related contact. NAACCR supplies standardized item definitions and exchange specifications, while NPCR, SEER, central registries, and CoC specify their applicable collection requirements. A field's presence in a software screen or data dictionary does not establish universal mandatory collection.
Apply it
For an applicable CoC abstract, the first facility visit to evaluate the cancer occurs January 8, and biopsy confirms it January 10. Collect Date of First Contact as January 8 and evaluate Class of Case from the documented locations of diagnosis and first-course treatment. For a separate central-registry export, apply that recipient's required-item specification; do not omit the CoC fields from the facility abstract merely because they are absent from that export.
Common pitfall: Diagnosis date and first contact can differ. Do not copy one date into the other automatically, treat every NAACCR-defined field as universally required, or use a CAP specimen protocol as a complete registry submission specification.
Standards for Oncology Registry Entry: STORE 2025 · ODS Certification Exam Content Outline
Cancer Registry Coding and Abstraction33.33% (60 of 180 items; calculated)
41.How should rule edition and diagnosis year guide abstraction?
Coding depends on the applicable manual, its effective instructions, and the case's diagnosis context. A newer publication may change a rule rather than simply clarify identical wording. Establish the governing edition before applying a remembered rule, then follow its instructions in order. For 2026 examination preparation, NCRA lists December 2024 Solid Tumor Rules and Summary Stage v3.3. Later practice publications are useful comparisons but cannot silently replace those examination-listed references.
Apply it
Two breast examples produce different primary counts under older and newer published rules. Before coding the exercise, the learner identifies its stipulated reference edition and follows that edition rather than selecting whichever answer matches the latest practice update.
Common pitfall: Publication recency alone does not establish applicability. Mixing an older rule number with a newer rule's wording can produce a confident but unsupported coding decision.
References for ODS Certification Examinations in 2026 · December 2025 Revision History for the Solid Tumor Rules
42.How is a single breast tumor's definitive histology converted to a code?
First determine the number of primaries with the applicable multiple-primary rules. Then apply the site's histology rules to the tumor or tumors assigned to each primary. Under the December 2024 Breast Solid Tumor Rules, a single tumor with one definitive histology is coded to that histology. Invasive ductal carcinoma, also termed invasive carcinoma of no special type or NST, is 8500/3; invasive lobular carcinoma is 8520/3. Grade is a separate characteristic and does not change ductal histology into lobular histology.
Apply it
Use the examination-listed December 2024 rules. An untreated patient has one left-breast tumor, and final pathology diagnoses only invasive ductal carcinoma, NST, grade 2. Establish one primary, select the Breast histology instructions for a single tumor, identify the single definitive invasive histology, and assign 8500/3. The morphology is 8500 and the malignant behavior is /3. Do not assign 8520/3 because no lobular carcinoma is diagnosed; record grade 2 in the applicable grade field.
Common pitfall: Do not select histology from grade, a biomarker, or an unconfirmed differential. A single tumor diagnosed as a mixed histology or containing both invasive and in situ components requires the relevant additional instructions; the one-histology example does not resolve those different cases.
References for ODS Certification Examinations in 2026 · SEER: Solid Tumor Rules · SEER Inquiry System: Question 20260004
43.When does the examination-era breast NST and lobular rule yield one primary?
The older Breast M10 described in SEER inquiry 20230010 combines NST/duct and lobular tumors in the same breast into one primary when no earlier multiple-primary rule applies. Its position matters: the specific rule is reached before a later different-histology-row rule. An earlier time-interval rule can already separate tumors. Apply this as an examination-era rule example with its stated conditions, rather than as an unrestricted statement about all breast cancers or current practice.
Apply it
Under the stipulated examination-era rules, synchronous separate NST/duct and lobular tumors occur in one breast, and no earlier rule applies. The learner assigns one primary under the older specific rule before reaching the later histology-row comparison.
Common pitfall: Do not let different table rows bypass a governing earlier rule. The same conclusion also cannot be carried into a revised edition that deleted that rule.
SEER Inquiry System: Question 20230010 · References for ODS Certification Examinations in 2026
45.How do clinical and pathological TNM classifications differ?
Clinical classification describes disease using the qualifying pretreatment clinical evidence, including examination, imaging, and appropriate diagnostic procedures. Pathological classification incorporates qualifying surgical and pathological evidence according to the applicable site rules. A pathology report can contribute to clinical assessment without automatically establishing a pathological classification. Determine both timing and eligibility. The discriminating issue is whether the required evidence and treatment circumstances satisfy that classification's rules, rather than whether any tissue diagnosis exists.
Apply it
A core biopsy confirms carcinoma and imaging describes local and nodal extent before treatment. The registrar supports clinical classification from those findings but does not assume that the biopsy alone supplies a complete pathological TNM classification.
Common pitfall: Pathological diagnosis and pathological stage are different concepts. A tissue-confirmed cancer may still lack the surgical assessment required for a particular pathological classification.
46.Which evidence distinguishes yc from yp after neoadjuvant therapy?
The y prefix indicates assessment during or after initial multimodality treatment in the relevant AJCC context. The accompanying c or p identifies the assessment basis: yc uses clinical assessment, while yp uses qualifying pathological assessment after therapy. Both differ from the original pretreatment clinical classification. Posttherapy imaging does not become pathological simply because treatment has occurred. Follow the applicable site and classification rules for the evidence available at each time point.
Apply it
After neoadjuvant therapy, imaging reassesses the tumor before surgery, and the later resection provides residual disease findings. The learner distinguishes the clinical posttherapy assessment as yc from the qualifying pathological posttherapy assessment as yp, retaining the original pretreatment classification separately.
Common pitfall: Do not select yp from timing alone. 'After therapy' establishes the posttherapy context, while the clinical or pathological assessment basis determines the accompanying classification.
47.How does depth of invasion determine a colon T category?
For colon carcinoma in AJCC eighth edition, T2 means invasion into the muscularis propria; T3 means invasion through that muscle into pericolorectal tissues. T4a means invasion through the visceral peritoneum. For T4b, distinguish clinical from pathological classification: gross adherence to an adjacent organ or structure supports cT4b without microscopic confirmation, whereas pT4b requires microscopic demonstration of direct invasion. If microscopic examination finds no tumor in the adhesion, assign pT1–pT4a according to the actual anatomical depth of invasion. Colon T categories depend on anatomical extent rather than a universal tumor-diameter threshold. NCI's colon staging tables explicitly explain this adherence distinction.
Apply it
An untreated sigmoid adenocarcinoma is resected. Pathology documents invasion through the muscularis propria into pericolic fat, without penetration of the visceral peritoneal surface or invasion of adjacent organs. Assign pT3: extension into pericolic tissue exceeds T2, while the stated findings do not satisfy T4a or T4b. A 3-cm diameter does not change this depth-based assignment. In a contrasting untreated case, the sigmoid tumor is grossly adherent to the bladder, supporting cT4b. Microscopic examination shows only inflammatory adhesion, no bladder invasion, and tumor confined to the muscularis propria. Assign pT2 based on the demonstrated depth. If microscopy instead demonstrated direct tumor invasion into the bladder, pT4b would apply.
Common pitfall: Pericolic fat invasion alone does not establish penetration of the visceral peritoneal surface. Likewise, gross adherence or removal of an adjacent organ does not independently establish pT4b. Preserve the distinction between clinical evidence of adherence and pathological evidence of invasion: an inflammatory adhesion can support cT4b while the pathological category is lower. A tumor-free adhesion does not automatically mean pT3; the actual depth may support pT1 through pT4a.
References for ODS Certification Examinations in 2026 · American College of Surgeons: AJCC Staging Rules · Colon Cancer Treatment (PDQ®) - NCI
48.How do named nodal chains distinguish regional from distant spread?
Regional lymph nodes are defined relative to the primary site. For a sigmoid colon primary, sigmoid mesenteric and inferior mesenteric nodes are regional; a supraclavicular node is nonregional. A confirmed metastasis in a regional node contributes to N classification, while a nonregional nodal metastasis contributes to distant classification. Under AJCC eighth-edition colon rules, N1a means one positive regional node. The exact primary and nodal chain are therefore decisive.
Apply it
After resection of an untreated sigmoid adenocarcinoma, one of 18 examined regional nodes is positive in the sigmoid mesentery, with no tumor deposits or other positive nodes. Assign pN1a. If the involved node were instead a biopsy-confirmed supraclavicular metastasis from that sigmoid primary, it would represent distant nodal spread rather than regional N1a disease.
Common pitfall: One positive node does not universally mean N1a across cancers. Confirm the chain is regional for the indexed primary before counting positive regional nodes, and do not classify every lymph-node metastasis as regional disease.
Summary Stage 2018 Coding Manual, Version 3.4 · American College of Surgeons: AJCC Staging Rules
49.What establishes distant metastatic disease for staging?
Distant disease involves spread beyond the primary and its defined regional extent, including qualifying nonregional organs or nodes. Establish the lesion's relationship to the primary and use the evidence standards of the applicable staging classification. A suspicious incidental lesion is not automatically a confirmed metastasis, and direct contiguous invasion is not interchangeable with a separate metastatic deposit. The decision requires both the anatomic relationship and sufficient documentation that the finding represents spread of the indexed cancer.
Apply it
A colorectal cancer record explicitly identifies a separate liver lesion as metastatic colorectal carcinoma. The registrar recognizes distant spread rather than a primary liver cancer, then applies the relevant staging system's documentation and classification rules.
Common pitfall: Do not equate every abnormal scan finding with metastasis. Also distinguish direct extension into an adjacent structure from a discontinuous deposit at a distant site.
NCI: Metastatic Cancer—When Cancer Spreads · Summary Stage 2018 Coding Manual, Version 3.4
50.How does Summary Stage distinguish in situ from invasive disease?
In situ disease remains within the epithelial compartment without invasion through the relevant basement membrane; invasive disease has crossed that boundary. In Summary Stage, in situ is a distinct category rather than a synonym for a small or early invasive tumor. Use the final diagnostic and extent evidence together with the applicable site instructions. A lesion's dimensions or negative nodes cannot convert documented invasion into in situ disease, because invasion concerns a different biologic boundary.
Apply it
A very small carcinoma has documented stromal invasion and no spread beyond the organ. The learner excludes the in situ category because invasion is present and evaluates localized invasive disease under the relevant Summary Stage instructions.
Common pitfall: Small size, screening detection, and clear margins do not establish in situ disease. The decisive distinction is the documented invasion boundary, interpreted under the applicable schema.
Summary Stage 2018 Coding Manual, Version 3.4 · SEER Training: SEER Summary Stage
51.When is invasive cancer localized in Summary Stage?
Localized disease is an invasive malignancy confined to the organ of origin under the relevant Summary Stage definition. It is distinct from in situ disease because invasion can be present within that organ. Determine the organ boundaries and assess evidence for regional or distant spread using the site-specific schema. Localized is an anatomic extent category, not a promise of favorable outcome, a particular tumor size, or a direct substitute for an AJCC stage group.
Apply it
A hypothetical schema defines all documented invasion as remaining within the primary organ, and the record establishes no regional or distant involvement. The learner selects localized Summary Stage despite the presence of invasion within that organ.
Common pitfall: Do not classify all invasive cancers as regional. Conversely, do not call a tumor localized solely because the primary was completely removed or had negative margins.
SEER Training: SEER Summary Stage · Summary Stage 2018 Coding Manual, Version 3.4
52.How does regional direct extension differ from localized disease?
Regional direct extension describes contiguous spread beyond the organ of origin into structures defined as regional by the applicable Summary Stage schema. Localized invasive disease remains within the defined organ boundaries. The name of an adjacent structure is therefore clinically important, but the schema determines its staging significance. Trace continuity of spread and compare the documented structure with the site-specific instructions instead of assigning a category from proximity or descriptive severity alone.
Apply it
A primary directly invades an adjacent structure that the stipulated schema lists as regional extension, with no involved nodes or distant disease. The learner chooses regional direct extension rather than localized disease or regional nodes only.
Common pitfall: Adjacent does not universally mean regional. Some boundaries have site-specific treatment, so use the schema's definitions rather than a general impression of nearby anatomy.
53.When does Summary Stage use regional lymph nodes only?
Regional lymph nodes only applies when the documented regional spread is nodal and the primary lacks qualifying regional direct extension, with no distant disease. A primary can still be invasive within its organ. Verify that the involved nodes are regional for that primary and that other extent findings do not change the category. The word 'only' distinguishes the mechanism of regional spread; it does not mean that the primary tumor itself is noninvasive.
Apply it
The primary remains within its organ, one node explicitly defined as regional is positive, and distant spread is excluded in the exercise. The learner selects regional lymph nodes only rather than localized or regional direct extension only.
Common pitfall: Positive regional nodes exclude localized disease in this scenario. However, they do not justify ignoring simultaneous regional extension or documented distant metastasis elsewhere.
54.How should combined regional extension and nodes be classified?
Summary Stage distinguishes regional direct extension, regional lymph-node involvement, and the combination of both. When the primary has qualifying regional direct extension and regional nodes are involved, preserve both mechanisms in the combined regional category, provided no distant disease controls the classification. Review all extent evidence before choosing among regional categories. Selecting the first regional finding encountered can discard additional documented spread and produce a less accurate abstraction.
Apply it
An exercise documents invasion into a schema-defined regional structure and metastasis in schema-defined regional nodes, without distant disease. The learner selects the combined regional extension-and-nodes category rather than choosing one regional mechanism and ignoring the other.
Common pitfall: Do not stop reading after identifying regional spread. A second regional mechanism changes the regional subcategory, while distant disease can change the overall extent category.
55.Why does distant spread control over concurrent regional findings?
Summary Stage summarizes the furthest documented extent of disease within its rules. When qualifying distant metastasis is present, concurrent regional extension or regional nodes do not reduce the case to a regional category. Preserve detailed regional information in the appropriate data fields, but classify the summary extent using the distant finding. The discriminating cue is a supported distant relationship, rather than which lesion is largest or which finding received the most treatment.
Apply it
A patient has regional nodal involvement and a separately documented metastatic deposit at a distant organ. The learner chooses distant Summary Stage while retaining the regional node findings in their applicable detailed fields for the abstract.
Common pitfall: The amount of regional disease does not outweigh distant spread. Likewise, complete removal of a distant deposit does not erase its role in the qualifying staging assessment.
Summary Stage 2018 Coding Manual, Version 3.4 · NCI: Metastatic Cancer—When Cancer Spreads
56.How does unknown extent differ from documented absence of spread?
Unknown extent reflects insufficient information to assign the relevant category; absence of spread is a supported finding interpreted under the schema's rules. A blank field or missing outside report is not equivalent to a negative assessment. First determine whether the available evidence and specific instructions permit a category. Seek missing information when appropriate, and retain uncertainty when necessary. The critical distinction is between a documented negative and a fact that was never established.
Apply it
An abstract contains only a diagnostic biopsy and lacks the outside staging workup. The registrar requests those records and does not label the case localized merely because the incomplete local chart contains no mention of metastasis.
Common pitfall: Silence in an incomplete chart is not proof of no spread. Avoid replacing uncertainty with a favorable category simply to complete every staging field.
Summary Stage 2018 Coding Manual, Version 3.4 · NCRA Professional Practice Code of Ethics
57.How is a complete colon TNM example converted to a stage group?
AJCC eighth-edition colon carcinoma stage IIA requires T3, N0, and M0. T3 identifies invasion through the muscularis propria into pericolorectal tissues; N0 means no regional nodal metastasis. M0 is established clinically rather than assigned as pM0. This conventional colon grouping uses the applicable T, N, and M categories; additional biomarkers are not required to select IIA. Other sites or prognostic grouping systems can require additional variables. NCI provides the [colon stage-group definitions](https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq).
Apply it
A patient undergoes qualifying sigmoid resection without neoadjuvant therapy. Adenocarcinoma extends through muscularis propria into pericolic fat, without visceral peritoneal penetration or adjacent-organ invasion. All 18 regional nodes are negative, no tumor deposits are present, and clinical staging establishes no distant metastasis. Assign pT3 pN0 cM0 and pathological stage group IIA under AJCC eighth edition.
Common pitfall: Do not write pM0 or infer M0 from a missing workup. Positive regional nodes would invalidate N0 and the IIA grouping. Summary Stage is a separate system and cannot replace this AJCC group.
American College of Surgeons: AJCC Staging Rules · References for ODS Certification Examinations in 2026
58.How is first-course treatment distinguished from treatment after progression?
First-course treatment is determined from the treatment plan and the applicable coding definitions, rather than a universal calendar cutoff. Planned components may occur at different times or facilities. Treatment introduced because of documented progression or recurrence requires evaluation as subsequent therapy instead of automatic inclusion in the initial course. Establish the sequence of the plan, delivery, and disease events. Timing supports interpretation, but the documented relationship to the treatment course is the key distinction.
Apply it
A patient's initial plan includes surgery followed by systemic therapy. Later, a new regimen begins specifically because progression is documented. The registrar evaluates the planned initial components as first course and separates the progression-driven regimen under the applicable treatment instructions.
Common pitfall: Do not use elapsed months alone to define first course. A late planned component and an early progression-driven change can have different treatment-course classifications.
59.When does chemotherapy refusal support code 87?
Under STORE, chemotherapy code 87 applies when chemotherapy was recommended but refused by the patient, family member, or guardian. It also applies when the patient refuses all treatment before any treatment is recommended; a separate chemotherapy recommendation is not required in that blanket-refusal circumstance. Both pathways require documented refusal. Distinguish code 00 for no chemotherapy planned or recommended, code 86 for recommended chemotherapy known not to have been administered without a stated reason, and code 88 when chemotherapy was recommended but administration is unknown.
Apply it
If an oncologist recommends chemotherapy and the patient explicitly declines, assign 87. Also assign 87 when the record documents refusal of all cancer treatment before recommendations are made. If recommended chemotherapy is known not to have been given but no reason is documented, use 86; if its administration cannot be established, use 88.
Common pitfall: Missing administration records or missed appointments do not establish refusal. A blanket refusal must concern all treatment; an undocumented recommendation is not itself evidence of blanket refusal.
60.How should multimodality treatment be abstracted across facilities?
A complete treatment abstract may require operative, radiation delivery, and systemic administration records from different facilities. Identify each modality separately and apply its own field definitions, dates, and level of detail. One documented modality does not establish another, and a local chart may contain only part of the patient's course. Reconcile external treatment evidence with the initial plan so the abstract represents supported delivered care rather than only care visible in one institution.
Apply it
Surgery occurred locally, radiation was delivered elsewhere, and systemic therapy was managed by a community oncologist. The registrar obtains the relevant delivery and administration records and codes each supported modality rather than treating the local surgery record as the entire course.
Common pitfall: Do not code external care as absent merely because local delivery fields are blank. Also avoid treating an outside consultation as proof that the proposed treatment occurred.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Distinguish public health disclosure permission from mandatory reporting, and apply individual authorization and documented research-waiver criteria.
- Separate casefinding completeness from field accuracy; practise independent audits, eligible-case denominators, central-registry consolidation edits, and targeted process improvement.
- Match CAP, CoC, NAACCR, NCCN, NPCR, and SEER to their functions, then select required data items and reportable conditions for the receiving program and applicable year.
- Recognize specimen location versus primary origin, provisional versus definitive hematopoietic diagnoses, RT-PCR versus FISH, and tumor biomarkers versus inherited findings.
- Compare the evidence supplied by PET, MRI, endoscopy, and biopsy, including the limits of metabolic uptake, anatomic imaging, and superficial tissue sampling.
- Use the governing rule edition and rule sequence to determine primary count and complete a histology assignment before abstracting stage and treatment.
- Work through colon T, nodal, and stage-group assignments, and distinguish clinical, pathological, yc, and yp assessment.
- Distinguish treatment mechanisms, first-course boundaries, documented administration, and chemotherapy refusal, including blanket refusal.
- Extend study beyond these selected lessons to the complete official outline and its additional disease-specific, laboratory, operational, and coding requirements.
A practical preparation plan
1. Build a domain coverage map
Use the official outline to list every topic, then mark which are addressed here and which need additional study. Allocate roughly one sixth of study to legal and ethical content, one quarter each to operations and identification, and one third to coding and abstraction.
2. Practise evidence-based identification
For each short record, identify the primary, histology, reportability decision, missing documents, and treatment evidence. Explain why each source supports that fact and which tempting inference it does not support.
3. Calculate and interpret registry measures
Work audit percentages, mean, median, risk ratios, and odds ratios by hand. Label every numerator, denominator, comparison direction, and study population before calculating, then state what the result can and cannot establish.
4. Apply one coding decision at a time
Establish the applicable edition, determine primary count, complete the histology assignment, select the appropriate staging classification, and then abstract treatment. For stage exercises, name the decisive anatomic boundary or assessment timing before selecting a category.
5. Review errors by mechanism
After the drills, classify each error as unsupported inference, wrong source, denominator error, rule-sequence error, edition mismatch, or classification confusion. Rework a fresh example with changed facts and explain why the answer changes.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- NCRA: Are You a Credential Holder?
- NCRA: ODS Exam
- 2026 Exam Handbook & Candidate Application
- ODS Certification Exam Content Outline
- References for ODS Certification Examinations in 2026
- NCRA Professional Practice Code of Ethics
- HHS: Patient Permission and Reporting to Public Health Authorities
- HHS: Does the Public Health Provision Require Disclosures?
- SEER Training: Population-Based Registries
- SEER Training: Casefinding Audits and Process Improvement
- SEER Training: Assessing Completeness
- SEER Training: Casefinding Introduction
- SEER Training: Pathology Reports
- SEER Training: Follow-Up Requirements
- NIST: Measures of Location
- CDC Field Epidemiology Manual: Analyzing and Interpreting Data
- NCI: Metastatic Cancer—When Cancer Spreads
- NCI: Pathology Reports
- NCI: Biomarker Testing for Cancer Treatment
- SEER: Solid Tumor Rules
- SEER: Summary Stage 2018
- Summary Stage 2018 Coding Manual, Version 3.4
- SEER Training: SEER Summary Stage
- American College of Surgeons: AJCC Staging Rules
- Standards for Oncology Registry Entry: STORE 2025
- SEER Inquiry System: Question 20230010
- November 2024 Revision History for the Solid Tumor Rules
- December 2025 Revision History for the Solid Tumor Rules
- SEER Inquiry System: Question 20260004
- AJCC Cancer Staging Rules: 8th Edition
- The Multiple Primary Rules (M rules)/Primary site and Histology Rules (PH rules) | SEER Training
- Transcript Biomarker Terminology – Speaking the Same Language | FDA
- Diagnostics Research and Development Resources - NCI
- Types of Cancer Treatment - NCI
- Tamoxifen Citrate - NCI
- Trastuzumab - NCI
- Colon Cancer Treatment (PDQ®) - NCI
- Current Cancer Protocols - CAP
- MRI (Magnetic Resonance Imaging) | FDA
- EANM/SNMMI guideline/procedure standard for [18F]FDG hybrid PET use in infection and inflammation in adults v2.0 - PMC
- About the Data Dictionary | NAACCR Data Dictionary
- Commission on Cancer | ACS
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.